Several laboratories currently offer panels of serum autoantibody assa
ys to screen women with unexplained infertility and those undergoing i
n vitro fertilization (IVF). Offering these tests implies that they ha
ve predictive value for the outcome of proposed infertility treatments
such that the results of the testing would alter clinical management.
Because screening for antiphospholipid antibodies adds expense to alr
eady costly procedures, it is an appropriate time to review the justif
ication for the use of these panels. (C) 1997 Elsevier Science Ireland
Ltd.